Home > Name List By 6 > 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one Argentina

CAS No 73963-72-1 , 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one Search by region : Argentina

  • Name: 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
  • Synonyms: OPC-13013; OPC 21; Cilostazole; 73963-72-1; OPC 13013; Cilostazolum; Pletaal; Cilostazolum [INN-Latin];6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one;Pletal;
  • CAS Registry Number:
  • Density: 1.34 g/cm3
  • Refractive index: 1.675
  • Water Solubility: DMSO: 18 mg/mL, soluble
  • Hazard Symbols: Xi: Irritant;
  • Molecular Weight: 369.46068
  • InchiKey: RRGUKTPIGVIEKM-UHFFFAOYSA-N
  • InChI: InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-
    19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
  • Molecular Formula: C20H27N5O2
  • Molecular Structure:CAS No:73963-72-1 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one

Related products

Select to

73963-72-1 Cilostazol

  • Cilostazol6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, >99,5
  • Argentina ARYL S.A. [Manufacturer]
  • Tel: 00541143150840
  • Fax: 00541143114455
  • Address: 141 4k Tucuman St.1049 Buenos AiresARGENTINA 1049 Buenos Aires,nullArgentina
Contact Supplier

Select to

1/1
References of 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
Title: Cilostazol
CAS Registry Number: 73963-72-1
CAS Name: 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
Synonyms: 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril; 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4-tetrahydro-2-oxoquinoline
Manufacturers' Codes: OPC-13013
Trademarks: Pletal (Otsuka)
Molecular Formula: C20H27N5O2
Molecular Weight: 369.46
Percent Composition: C 65.02%, H 7.37%, N 18.96%, O 8.66%
Literature References: Phosphodiesterase (PDE III) inhibitor; induces vasodilation and inhibits platelet aggregation. Prepn: BE 878548; T. Nishi, K. Nakagawa, US 4277479 (1979, 1981 both to Otsuka); T. Nishi et al., Chem. Pharm. Bull. 31, 1151 (1983). Physical properties: T. Shimizu et al., Arzneim.-Forsch. 35, 1117 (1985). HPLC determn in plasma: H. Akiyama et al., J. Chromatogr. 338, 456 (1985). Acute toxicity study: G. Nomura et al., Iyakuhin Kenkyu 16, 1200 (1985), C.A. 104, 102207f (1986). Clinical pharmacokinetics: A. Suri et al., J. Clin. Pharmacol. 38, 144 (1998). Clinical evaluation to prevent stent thrombosis: S.-W. Park et al., Am. J. Cardiol. 84, 511 (1999); to prevent restenosis after angioplasty: E. Tsuchikane et al., Circulation 100, 21 (1999). Review of pharmacology and clinical efficacy in intermittent claudication: E. M. Sorkin, A. Markham, Drugs Aging 14, 63-71 (1999).
Properties: Colorless needle-like crystals from methanol, mp 159.4-160.3°. uv max (methanol): 257 nm (e 15200). Freely sol in acetic acid, chloroform, n-methyl-2-pyrrolidone, DMSO. Practically insol in ether, water, 0.1N HCl, 0.1N NaOH. LD50 in mice, rats (mg/kg): >2000, >2000 i.p.; >5000, >5000 orally (Nomura).
Melting point: mp 159.4-160.3°
Absorption maximum: uv max (methanol): 257 nm (e 15200)
Toxicity data: LD50 in mice, rats (mg/kg): >2000, >2000 i.p.; >5000, >5000 orally (Nomura)
Therap-Cat: Antithrombotic; in treatment of intermittent claudication.
Keywords: Antithrombotic; Phosphodiesterase Inhibitor.